Receive our newsletter – data, insights and analysis delivered to you

Covid-19 Vaccination

Latest news, daily rates, information and updates

Last updated 22 January, 2022 10:30 CEST

As the coronavirus vaccine rolls out across the globe on this page you will find all our latest Covid-19 vaccine updates and live tracking of vaccine development and administration.

You can explore our data and find insights into Covid-19 vaccine clinical trials, country-level vaccination statistics, the impact of vaccination on infection and death rates, and all the latest news and information on the Covid-19 vaccination.

Number of vaccine doses administered globally

9,847,181,171

+27,521,151 reported yesterday

Number of fully vaccinated globally

4,085,477,219

+14,912,135 reported yesterday

Number of countries with a vaccination programme

217

+2 reported yesterday

Fully vaccinated global population

0.9%

+39.999999999996% reported yesterday

Coronavirus vaccine roll out statistics by country

Public health authorities across the globe have been mobilising to deliver the biggest ever vaccination programme to battle Covid-19. How many people have received the Covid-19 vaccine? We bring you the latest Covid-19 vaccine numbers, including daily Covid-19 vaccine rates per country. Track worldwide Covid-19 vaccine rates with Pharmaceutical Technology and GlobalData.

Some countries have made a fast start with their vaccination efforts. By the end of January, Israel had successfully vaccinated 3 million people with the first dose. While the US may have had a slow start, President Biden has put the vaccination programme at the forefront of his first 100 days agenda.

Country Doses Administered Doses per 1000 Fully Vaccinated Population (%) Vaccine being used in a country
World 9,847,181,171 1,296.7 5380 %
China 2,960,675,000 2,125.8 8792 % CanSino, Sinopharm/Beijing, Sinopharm/Wuhan, Sinovac, ZF2001
India 1,609,613,007 1,190.0 5005 % Covaxin, Oxford/AstraZeneca, Sputnik V
United States 532,850,229 1,628.7 6396 % Johnson&Johnson, Moderna, Pfizer/BioNTech
Brazil 351,485,976 1,678.0 7076 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Indonesia 303,188,927 1,132.7 4444 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Japan 202,865,566 1,603.3 7874 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Pakistan 170,711,868 804.4 3716 % CanSino, Covaxin, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
Vietnam 162,375,421 1,699.5 4561 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Germany 161,709,631 1,950.0 7349 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Mexico 158,656,184 1,257.3 6050 % CanSino, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V
Bangladesh 151,390,044 938.2 3595 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Russia 151,194,542 1,036.0 4730 % EpiVacCorona, Sputnik V
Turkey 140,556,373 1,707.4 6346 % Pfizer/BioNTech, Sinovac
United Kingdom 137,140,907 2,062.6 7237 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Iran 127,687,808 1,520.2 6360 % Covaxin, COVIran Barekat, Oxford/AstraZeneca, Sinopharm/Beijing, Soberana02, Sputnik V
France 125,938,809 1,880.0 7444 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Italy 123,280,611 2,040.0 7540 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Philippines 122,313,496 1,146.8 5329 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
South Korea 111,794,915 2,165.1 8479 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Thailand 110,799,936 1,595.9 6890 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Spain 86,237,508 1,845.7 8104 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Argentina 84,614,437 1,901.7 7687 % CanSino, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Canada 75,423,792 2,035.2 8029 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Malaysia 61,946,138 1,922.2 7973 % CanSino, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Saudi Arabia 54,868,494 1,628.1 6984 % Oxford/AstraZeneca, Pfizer/BioNTech
Colombia 53,986,327 1,087.4 4766 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Peru 51,466,857 1,608.9 6843 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Morocco 51,203,047 1,421.2 6406 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm, Sinopharm/Beijing, Sputnik V
Poland 50,500,491 1,329.7 5677 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Australia 47,698,880 1,908.5 8042 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Chile 46,160,384 2,464.6 9000 % CanSino, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Uzbekistan 41,142,077 1,248.4 1785 % Moderna, Oxford/AstraZeneca, Sputnik V, ZF2001
Taiwan 39,795,263 1,685.5 7267 % Medigen, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Egypt 36,906,765 360.6 1370 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm, Sinopharm/Beijing, Sinovac, Sputnik V
Sri Lanka 35,100,585 1,619.8 6405 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Netherlands 31,970,282 1,855.4 7128 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Cambodia 31,874,687 1,961.5 8443 % Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac
Venezuela 30,049,714 1,040.9 4021 % Abdala, Sinopharm/Beijing, Sinovac, Sputnik V
Ukraine 29,581,886 662.9 3241 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
South Africa 29,339,383 507.8 2830 % Johnson&Johnson, Pfizer/BioNTech
Cuba 27,872,484 2,458.3 7982 % Abdala, Soberana02
Ecuador 24,662,847 1,443.6 6535 % CanSino, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Belgium 23,637,466 2,069.5 7742 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
United Arab Emirates 23,176,828 2,352.9 9368 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm, Sinopharm/Beijing, Sinopharm/Wuhan, Sputnik V
Portugal 20,718,825 2,015.1 8928 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Greece 18,729,211 1,745.9 6733 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Sweden 18,722,999 1,838.6 7384 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Kazakhstan 17,772,417 972.4 4743 % QazVac, Sinopharm/Beijing, Sputnik V
Israel 17,746,020 1,997.6 6812 % Moderna, Pfizer/BioNTech
Mozambique 17,710,506 600.4 2641 % Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing
Nigeria 17,575,151 89.7 252 % Oxford/AstraZeneca
Austria 17,317,592 1,957.4 7568 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Czechia 16,769,554 1,578.2 6354 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Nepal 16,536,009 588.7 2714 % Covaxin, Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Romania 16,282,491 836.1 4077 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Rwanda 15,658,591 1,272.9 4617 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
Hungary 15,582,861 1,595.2 6217 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Iraq 14,714,511 382.9 1547 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Switzerland 14,566,040 1,710.3 6895 % Moderna, Pfizer/BioNTech
Dominican Republic 14,466,737 1,361.3 5421 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Denmark 12,952,186 2,234.1 8118 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Angola 12,690,132 411.9 1399 % Oxford/AstraZeneca
Tunisia 12,573,385 1,087.2 5303 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
Singapore 12,132,375 2,151.6 8382 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Azerbaijan 11,765,037 1,183.3 4752 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V
Kenya 11,437,774 222.6 975 % Oxford/AstraZeneca, Sputnik V
Bolivia 11,408,180 1,004.8 4430 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Guatemala 11,247,608 652.1 2696 % Moderna, Oxford/AstraZeneca
Ethiopia 10,958,596 100.3 146 % Oxford/AstraZeneca
Hong Kong 10,718,798 1,417.8 6271 % Pfizer/BioNTech, Sinovac
Finland 10,461,909 1,895.9 7427 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Norway 10,329,408 1,943.7 7433 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Honduras 10,272,600 1,071.5 4570 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik V
Ireland 10,262,820 2,114.5 7954 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Algeria 9,989,662 236.6 989 % Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac, Sputnik V
Uganda 9,763,030 228.5 330 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
El Salvador 9,651,029 1,503.1 6486 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Ghana 9,600,792 322.5 980 % Oxford/AstraZeneca, Sputnik V
Myanmar 9,001,616 167.6 646 % Oxford/AstraZeneca, Sinopharm/Beijing
New Zealand 8,886,836 1,819.0 8001 % Pfizer/BioNTech
Nicaragua 8,403,579 1,299.8 5121 % Abdala, Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Soberana02, Sputnik Light, Sputnik V
Serbia 8,324,076 1,192.2 4626 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm, Sinopharm/Beijing, Sputnik V
Jordan 8,265,793 830.2 3951 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Costa Rica 8,016,478 1,603.5 7182 % Oxford/AstraZeneca, Pfizer/BioNTech
Zimbabwe 7,496,882 519.2 2259 % Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac, Sputnik V
Paraguay 7,410,811 1,065.4 4420 % Covaxin, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
Uruguay 7,284,987 2,112.0 7793 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Kuwait 7,214,597 1,743.8 7833 % Pfizer/BioNTech
Slovakia 6,492,666 1,192.0 4811 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik V
Panama 6,376,734 1,526.7 5968 % Oxford/AstraZeneca, Pfizer/BioNTech
Oman 6,375,600 1,320.1 6080 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V
Belarus 5,685,092 599.4 2557 % Sinopharm/Beijing, Sputnik V
Qatar 5,586,386 2,008.3 7975 % Moderna, Pfizer/BioNTech
Mongolia 5,426,161 1,711.6 6842 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Sudan 5,251,235 125.6 295 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Tajikistan 5,059,324 555.9 2496 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V
Croatia 5,033,759 1,230.9 5364 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Afghanistan 5,004,050 134.6 1032 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Lebanon 4,781,398 698.1 2866 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Laos 4,402,770 605.1 3816 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Lithuania 4,371,199 1,567.0 6649 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Bulgaria 4,091,684 582.5 2812 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Cote d'Ivoire 3,845,788 153.4 469 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Bahrain 3,323,673 2,117.7 7588 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm, Sinopharm/Beijing, Sputnik V
Palestine 2,974,583 583.1 2626 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Slovenia 2,892,684 1,399.2 5837 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Libya 2,864,201 428.9 1381 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
Latvia 2,735,078 1,419.7 6655 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Georgia 2,651,265 710.6 3231 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac
Guinea 2,443,497 196.8 640 % Sputnik V
Tanzania 2,431,769 43.2 241 % Johnson&Johnson, Pfizer/BioNTech, Sinopharm/Beijing
Mauritania 2,424,087 550.5 2199 % Oxford/AstraZeneca, Sinopharm/Beijing
Kyrgyzstan 2,413,333 382.1 1598 % Sinopharm/Beijing, Sputnik V
Albania 2,398,207 836.7 3699 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V
Senegal 2,360,122 148.9 627 % Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing
Zambia 2,258,222 130.1 912 % Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing
Botswana 2,210,690 980.7 4610 % Covaxin, Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Mauritius 2,077,156 1,641.6 7235 % Covaxin, Oxford/AstraZeneca, Sinopharm/Beijing
Moldova 1,884,181 531.4 2835 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Malawi 1,864,968 102.8 421 % Johnson&Johnson, Oxford/AstraZeneca
Armenia 1,761,529 596.8 2659 % Moderna, Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac, Sputnik V
Kosovo 1,732,948 939.1 4331 % Oxford/AstraZeneca, Pfizer/BioNTech
North Macedonia 1,675,793 804.5 3792 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
Mali 1,652,365 86.6 331 % Oxford/AstraZeneca
Cyprus 1,618,223 1,277.5 4891 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Estonia 1,533,728 1,161.1 6254 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Togo 1,507,722 191.1 645 % Oxford/AstraZeneca
Trinidad and Tobago 1,464,353 1,053.6 4917 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Somalia 1,453,959 96.9 514 % Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac
Syria 1,342,360 76.7 413 % Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing, Sinovac, Sputnik Light, Sputnik V
Congo 1,295,601 15.4 67 % Moderna, Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V
Jamaica 1,282,313 436.9 2069 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Fiji 1,276,260 1,444.6 6930 % Oxford/AstraZeneca
Bosnia and Herzegovina 1,242,203 373.7 1528 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac, Sputnik V
Malta 1,191,768 2,464.7 9189 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Benin 1,144,390 99.6 764 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Cameroon 1,024,333 40.6 263 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Macao 1,020,354 1,615.4 7478 % Pfizer/BioNTech, Sinopharm/Beijing
Bhutan 1,010,129 1,339.0 6305 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Madagascar 971,426 37.0 292 % Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing
Niger 963,041 42.9 204 % Oxford/AstraZeneca, Sinopharm/Beijing
Sierra Leone 923,880 120.8 504 % Oxford/AstraZeneca, Sinopharm/Beijing
Central African Republic 902,347 193.4 742 % Covaxin, Oxford/AstraZeneca
Luxembourg 877,632 1,444.1 5924 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Brunei 790,506 1,701.9 8298 % Oxford/AstraZeneca, Sinopharm/Beijing
Burkina Faso 776,941 37.3 160 % Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing
Maldives 772,056 1,497.1 7060 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Iceland 760,737 2,151.6 8079 % Johnson&Johnson, Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Yemen 759,220 26.6 124 % Johnson&Johnson, Oxford/AstraZeneca, Sinovac
Guyana 757,464 972.3 3939 % Oxford/AstraZeneca, Sputnik V
Lesotho 688,097 326.4 3041 % Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing
Namibia 661,079 270.0 1450 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Montenegro 649,450 1,043.6 4445 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Northern Cyprus 617,389 1,657.5 7409 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinovac
Cape Verde 611,615 1,100.1 4821 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Liberia 589,628 122.4 948 % Oxford/AstraZeneca
Gabon 566,021 267.1 817 % Pfizer/BioNTech, Sinopharm/Beijing, Sputnik V
Papua New Guinea 516,457 60.0 264 % Oxford/AstraZeneca
Suriname 495,009 859.4 4017 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Comoros 476,350 572.3 2381 % Covaxin, Oxford/AstraZeneca, Sinopharm/Beijing
Equatorial Guinea 443,135 338.5 1502 % Sinopharm/Beijing
Eswatini 434,201 382.2 2808 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech
Guinea-Bissau 416,500 222.2 129 % Oxford/AstraZeneca, Sinopharm/Beijing
Belize 412,002 1,075.5 5096 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Chad 381,189 24.6 62 % Sinopharm/Beijing
New Caledonia 360,890 1,238.6 6044 % Pfizer/BioNTech
French Polynesia 342,983 1,235.2 5980 % Johnson&Johnson, Pfizer/BioNTech
Bahamas 312,840 811.2 3899 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech
Barbados 302,255 1,054.5 5066 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Democratic Republic of Congo 291,286 3.5 13 % Oxford/AstraZeneca
South Sudan 288,900 26.3 182 % Johnson&Johnson, Oxford/AstraZeneca
Gambia 268,008 117.5 978 % Johnson&Johnson, Oxford/AstraZeneca, Sinopharm/Beijing
Samoa 265,421 1,353.3 6295 % Oxford/AstraZeneca
Solomon Islands 256,766 393.3 1010 % Oxford/AstraZeneca
Curacao 238,049 1,489.2 6093 % Moderna, Pfizer/BioNTech
Djibouti 207,952 216.9 1032 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing, Sinovac, Sputnik V
Haiti 190,063 17.1 63 % Johnson&Johnson, Moderna
Jersey 187,228 1,736.8 6988 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Isle of Man 184,275 2,191.7 7854 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Seychelles 183,472 1,896.1 8088 % Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V
Aruba 165,593 1,564.5 7523 % Pfizer/BioNTech
Vanuatu 152,711 521.8 1722 % Oxford/AstraZeneca
Sao Tome and Principe 151,040 715.7 2910 % Oxford/AstraZeneca
Guernsey 145,112 2,314.2 2172 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Tonga 138,684 1,312.1 6119 % Oxford/AstraZeneca
Cayman Islands 125,717 1,959.0 8755 % Oxford/AstraZeneca, Pfizer/BioNTech
Bermuda 115,624 1,807.5 7156 % Oxford/AstraZeneca, Pfizer/BioNTech
Antigua and Barbuda 115,487 1,199.4 5681 % Oxford/AstraZeneca, Pfizer/BioNTech, Sputnik V
Gibraltar 109,828 3,257.3 11952 % Pfizer/BioNTech
Saint Lucia 107,399 590.5 2787 % Oxford/AstraZeneca, Pfizer/BioNTech
Faeroe Islands 101,803 0 % Moderna, Pfizer/BioNTech
Greenland 79,430 1,417.8 6838 % Moderna, Pfizer/BioNTech
Grenada 75,154 674.3 3104 % Johnson&Johnson, Oxford/AstraZeneca, Pfizer/BioNTech
Liechtenstein 66,197 1,746.2 6806 % Moderna, Pfizer/BioNTech
Saint Vincent and the Grenadines 61,198 555.3 2381 % Oxford/AstraZeneca
Dominica 59,946 836.9 4024 % Oxford/AstraZeneca, Pfizer/BioNTech, Sinopharm/Beijing
Saint Kitts and Nevis 56,410 1,059.9 4871 % Oxford/AstraZeneca, Pfizer/BioNTech
Sint Maarten (Dutch part) 51,856 1,275.5 6130 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Monaco 49,980 1,292.1 6026 % Pfizer/BioNTech
Turks and Caicos Islands 49,107 1,303.8 6235 % Pfizer/BioNTech
San Marino 47,100 1,394.1 7233 % Pfizer/BioNTech, Sputnik V
Turkmenistan 41,993 7.0 16 % EpiVacCorona, Oxford/AstraZeneca, Sinopharm/Beijing, Sputnik V
Anguilla 21,256 1,176.6 5158 % Oxford/AstraZeneca, Pfizer/BioNTech
Andorra 19,064 247.6 164 % Moderna, Oxford/AstraZeneca, Pfizer/BioNTech
Nauru 15,128 1,190.8 5797 % Oxford/AstraZeneca
Wallis and Futuna 12,287 777.2 3881 % Moderna
Burundi 9,007 0.8 3 % Sinopharm/Beijing
Bonaire Sint Eustatius and Saba 7,391 275.7 621 % Moderna, Pfizer/BioNTech
Tuvalu 4,772 405.0 0 % Oxford/AstraZeneca
Falkland Islands 4,322 1,070.1 4251 % Oxford/AstraZeneca
Saint Helena 3,107 393.1 0 % Oxford/AstraZeneca
Montserrat 1,306 243.7 362 % Oxford/AstraZeneca
Micronesia (country) 0 0.0 0 %
Marshall Islands 0 0.0 0 %
Timor-Leste 0 0.0 0 %
Eritrea 0 0.0 0 %
Vatican 0 0.0 0 %

World map of vaccinations – total doses and fully vaccinated

GlobalData brings you a map of total worldwide Covid-19 vaccination rates per country, which lets you track Covid-19 vaccine numbers as they happen each day.

Total doses tracks the number of vaccine doses applied, whether they be the first or second of the two dose treatments or the one dose vaccine. Fully vaccinated captures the combined number of people to have received either both shots of a two-stage vaccine or the one-shot vaccine. See which countries are administering most Covid-19 vaccines and where efforts are falling short.

The first ever dose of Covid-19 vaccine was administered in the UK in December 2020, and the global vaccination effort has fast expanded with most countries beginning to start their vaccination programmes.

However, supply issues which have hit the EU in January and vaccine poverty fears in the developing world still pose challenges for the worldwide Covid-19 vaccine roll-out.

GlobalData brings you a map of total worldwide Covid-19 vaccination rates per country, which lets you track Covid-19 vaccine first dose and second dose numbers as they happen each day. See which countries are administering most Covid-19 vaccines and where efforts are falling short.

With the worldwide first dose vaccination administered in the UK in December 2020, the global Covid-19 vaccination effort has fast expanded with most countries beginning to start their vaccination programmes. However, supply issues which have hit the EU in January and vaccine poverty fears in the developing world still pose challenges for the worldwide Covid-19 vaccine roll-out.

Global Covid-19 vaccinations

This Covid-19 vaccination chart shows a steadily growing Covid-19 vaccination rate globally since January 2021, the first full month of the global Covid-19 vaccination drive. For more details also see GlobalData’s intelligence on Covid-19 vaccinations per country.

Country-level Covid-19 vaccination

With Israel having a head start with Covid-19 vaccine numbers, many countries are stepping up their effort to battle new cases and death rates with fast Covid-19 vaccine roll-outs.

Vaccines administered

Vaccine doses per 1,000 people

Fully vaccinated population

Leading vaccine candidates and current status

At the start of February nine approved Covid-19 vaccines were being used globally to fight the rising global death rate from Covid-19. The Janssen vaccine is likely to achieve imminent approval and there are almost 50 other Covid-19 vaccines still in development. Some might never progress to regulatory approval, but with new variants of Covid-19 spreading fast the race for the most effective and affordable Covid-19 vaccine is still on. Follow GlobalData’s tracker on Covid-19 vaccine initiatives and Covid-19 vaccine trials here:

Progress: Trial Results expected Awaiting approval Available to public
Trial size Doses requierd Storage temperature Efficacy Number of countries approved

Pfizer/BioNTech 46,331 2 8°C to -90°C 95.0% 45

mRNA vaccine, first to demonstrate positive Phase 3 results. Impressive efficacy of 95% in prevention of Covid-19, with a single drawback of requiring unusually cold (-70 degrees F) conditions for storage and transportation.

Trial Start Date - 29 April 2020
Result Publication Date - 18 November 2020
28 Nov, 2021: Complete Approval given by Egypt
19 Nov, 2021: Complete Approval given by Canada
19 Nov, 2021: EUA Approval given by US
10 Nov, 2021: Complete Approval given by Japan
9 Nov, 2021: Complete Approval given by Canada
29 Oct, 2021: Emergency Use Authorization given by US
12 Oct, 2021: Emergency Use Authorization given by Australia
8 Oct, 2021: Emergency Use Authorization given by Malaysia
22 Sep, 2021: Emergency Use Authorization given by US
16 Sep, 2021: Complete Approval given by Canada
23 Jun, 2021: Emergency Use Authorization given by Australia
15 Jul, 2021: Emergency Use Authorization given by Indonesia
24 Jun, 2021: Emergency Use Authorization given by Thailand
21 Jun, 2021: Complete Approval given by New-Zealand
15 Jun, 2021: Emergency Use Authorization given by Malaysia
15 Jun, 2021: Complete Approval given by US
12 Jun, 2021: Emergency Use Authorization given by Vietnam
11 Jun, 2021: Complete Approval given by Brazil
4 Jun, 2021: Emergency Use Authorization given by UK
2 Jun, 2021: Emergency Use Authorization given by Zambia
31 May, 2021: Emergency Use Authorization given by Pakistan
31 May, 2021: Emergency Use Authorization given by Italy
28 May,2021: Complete Approval given by EU
27 May, 2021: Emergency Use Authorization given by Bangladesh
13 May, 2021: Emergency Use Authorization given by United Arab Emirates
10 May, 2021: Emergency Use Authorization given by US
7 May, 2021: Emergency Use Authorization given by Sri Lanka
6 May, 2021: Emergency Use Authorization given by Canada
21 Mar, 2021: Emergency Use Authorization given by Libya
16 Mar, 2021: Emergency Use Authorization given by South Africa
15 Mar, 2021: Emergency Use Authorization given by Maldives
5 Mar, 2021: Emergency Use Authorization given by Republic of Korea
1 Mar,2021: Complete Approval given by Denmark
23 Feb,2021: Complete Approval given by Brazil
14 Feb,2021: Complete Approval given by Japan
10 Feb, 2021: Emergency Use Authorization given by New Zealand
2 Feb, 2021: Emergency Use Authorization given by Peru
25 Jan, 2021: Complete Approval given by Australia
25 Jan, 2021: Emergency Use Authorization given by Hong Kong
13 Jan, 2021: Emergency Use Authorization given by Philippines
11 Jan, 2021: Emergency Use Authorization given by Mongolia
6 Jan, 2021: Emergency Use Authorization given by Colombia
27 Dec, 2020: Emergency Use Authorization given by Iraq
25 Dec, 2020: Emergency Use Authorization given by Ireland
23 Dec, 2020: Emergency Use Authorization given by Argentina
21 Dec, 2020: Complete Approval given by EU
21 Dec, 2020: Emergency Use Authorization given by Qatar
19 Dec, 2020: Complete Approval given by Switzerland
17 Dec, 2020: Emergency Use Authorization given by Ecuador
16 Dec, 2020: Emergency Use Authorization given by Panama
16 Dec, 2020: Emergency Use Authorization given by Chile
16 Dec, 2020: Emergency Use Authorization given by Costa Rica
15 Dec, 2020: Emergency Use Authorization given by Oman
15 Dec, 2020: Emergency Use Authorization given by Jordan
14 Dec, 2020: Emergency Use Authorization given by Singapore
13 Dec, 2020: Emergency Use Authorization given by Kuwait
12 Dec, 2020: Emergency Use Authorization given by Mexico
11 Dec, 2020: Emergency Use Authorization given by US
10 Dec, 2020: Emergency Use Authorization given by Saudia Arabia
9 Dec, 2020: Emergency Use Authorization given by Canada
4 Dec, 2020: Emergency Use Authorization given by Bahrain
2 Dec, 2020: Emergency Use Authorization given by UK
Today

Moderna 30,420 2 8°C to -20°C 94.5% 30

Like Pfizer/BioNTech’s offering, is an mRNA vaccine with a nearly identical 95% efficacy for prevention of Covid-19. Also requires freezing temperatures but does not require ultra-low temperatures as Pfizer/BioNTech’s vaccine does.

Trial Start Date - 27 July 2020
Result Publication Date - 16 November 2020
19 Nov, 2021: EUA Approval given by US
12 Nov, 2021: Complete Approval given by Canada
20 Oct, 2021: Emergency Use Authorization given by the US
5 Oct, 2021: Emergency Use Authorization given by EU
16 Sep, 2021: Complete Approval given by Canada
5 Sep, 2021: Emergency Use Authorization given by Australia
4 Sep, 2021: Emergency Use Authorization given by Philippines
19 Aug, 2021: Emergency Use Authorization given by Mexico
13 Aug, 2021: Emergency Use Authorization given by US
9 Aug, 2021: Emergency Use Authorization given by Australia
5 Aug, 2021: Emergency Use Authorization given by Malaysia
30 Jul, 2021: Emergency Use Authorization given by Lithuania
2 Jul, 2021: Emergency Use Authorization given by Italy
26 Jul, 2021: Emergency Use Authorization given by Bhutan
9 Jul, 2021: Emergency Use Authorization given by Saudia Arabia
4 Jul, 2021: Emergency Use Authorization given by United Arab Emirates
2 Jul, 2021: Emergency Use Authorization given by Indonesia
30 Jun, 2021: Emergency Use Authorization given by India
30 Jun, 2021: Emergency Use Authorization given by Bangladesh
29 Jun, 2021: Emergency Use Authorization given by Vietnam
8 Jun, 2021: Emergency Use Authorization given by Maldives
21 May, 2021: Complete Approval given by South Korea
21 May, 2021: Emergency Use Authorization given by Japan
13 May, 2021: Emergency Use Authorization given by Thailand
6 May, 2021: Emergency Use Authorization given by Taiwan
13 May, 2021: Emergency Use Authorization given by Philippines
30 Apr, 2021: Emergency Use Listing (EUL) given by WHO
21 Mar, 2021: Emergency Use Authorization given by Libya
9 Feb, 2021: Emergency Use Authorization given by Qatar
3 Feb, 2021: Emergency Use Authorization given by Singapore
12 Jan, 2021: Emergency Use Authorization given by Switzerland
11 Jan, 2021: Emergency Use Authorization given by Mongolia
8 Jan, 2021: Emergency Use Authorization given by UK
8 Jan, 2021: Emergency Use Authorization given by France
6 Jan, 2021: Complete Approval given by EU
4 Jan, 2021: Authorization to import given by Israel
23 Dec, 2020: Emergency Use Authorization given by Canada
18 Dec, 2020: Emergency Use Authorization given by US
Today

AstraZeneca Plc 24,820 2 2 - 8°C 70.4 52

Adenoviral vaccine which has produced mixed results depending on region, vaccine dosing regimen, and schedule. While overall efficacy may be lower than some competitors, protections against hospitalization and death is strong.

Trial Start Date - 28 May 2020
Result Publication Date - 08 December 2020
17 Nov, 2021: Emergency Use Authorization given by Malaysia
28 Jul, 2021: Emergency Use Authorization given by New Zealand
2 Jun, 2021: Emergency Use Authorization given by Zambia
21 May, 2021: Emergency Use Authorization given by Japan
21 Mar, 2021: Emergency Use Authorization given by Libya
25 Mar, 2021: Emergency Use Authorization given by Finland
25 Mar, 2021: Emergency Use Authorization given by Iceland
18 Mar, 2021: Emergency Use Authorization given by Portugal
10 Mar, 2021: Emergency Use Authorization given by Papua New Guinea
10 Mar, 2021: Emergency Use Authorization given by Portugal
8 Mar, 2021: Emergency Use Authorization given by Indonesia
2 Mar, 2021: Emergency Use Authorization given by Malaysia
26 Feb, 2021: Emergency Use Authorization given by Canada
26 Feb, 2021: Emergency Use Authorization given by Costa Rica
24 Feb, 2021: Emergency Use Authorization given by Colombia
22 Feb, 2021: Emergency Use Authorization given by Ukraine
18 Feb, 2021: Emergency Use Authorization given by Saudi Arabia
18 Feb, 2021: Emergency Use Authorization given by Nigeria
17 Feb, 2021: Emergency Use Authorization given by Iran
16 Feb, 2021: Emergency Use Authorization given by Australia
15 Feb, 2021: Emergency Use Listing (EUL) given by WHO
12 Feb, 2021: Emergency Use Authorization given by Cambodia
10 Feb, 2021: Emergency Use Authorization given by South Korea
6 Feb, 2021: Complete Approval given by Spain
5 Feb, 2021: Emergency Use Authorization given by Greece
2 Feb, 2021: Complete Approval given by France
2 Feb, 2021: Complete Approval given by Sweden
1 Feb, 2021: Emergency Use Authorization given by Vietnam
1 Feb, 2021: Emergency Use Authorization given by Egypt
31 Jan, 2021: Emergency Use Authorization given by Kuwait
30 Jan, 2021: Complete Approval given by Italy
29 Jan, 2021: Complete Approval given by EU
29 Jan, 2021: Emergency Use Authorization given by Philippines
27 Jan, 2021: Emergency Use Authorization given by Chile
24 Jan, 2021: Emergency Use Authorization given by Ecuador
23 Jan, 2021: Emergency Use Authorization given by South Africa
23 Jan, 2021: Emergency Use Authorization given by Bhutan
22 Jan, 2021: Emergency Use Authorization given by Sri Lanka
21 Jan, 2021: Emergency Use Authorization given by Thailand
21 Jan, 2021: Emergency Use Authorization given by Hungary
19 Jan, 2021: Emergency Use Authorization given by Iraq
18 Jan, 2021: Emergency Use Authorization given by Brazil
17 Jan, 2021: Emergency Use Authorization given by Pakistan
15 Jan, 2021: Emergency Use Authorization given by Nepal
11 Jan, 2021: Emergency Use Authorization given by Mongolia
8 Jan, 2021: Emergency Use Authorization given by Bangladesh
6 Jan, 2021: Emergency Use Authorization given by India
6 Jan, 2021: Emergency Use Authorization given by Argentina
6 Jan, 2021: Emergency Use Authorization given by Dominican Republic
6 Jan, 2021: Emergency Use Authorization given by El Salvador
6 Jan, 2021: Emergency Use Authorization given by Mexico
6 Jan, 2021: Emergency Use Authorization given by Morocco
30 Dec, 2020: Emergency Use Authorization given by UK
Today

Novavax Inc 15,203 2 2 - 8°C 90.4% 2

Uses virus-like particles (VLPs) produced in insect cells and demonstrated 100% efficacy against variants "not considered Variants of Concern/Interest" and 93% efficacy against predominantly circulating Variants of Concern and Variants of Interest

Trial Start Date - 28 September 2020
Result Publication Date - 11 March 2021
18 Nov, 2021: Emergency Use Authorization given by Philippine
1 Nov, 2021: Emergency Use Authorization given by Indonesia
Today

Johnson & Johnson 44,325 1 2 - 8°C 66.0% 32

Adenoviral vaccine able to confer nearly 70% protection against all Covid-19 with a single dose. Like AstraZeneca’s vaccine, overall protection is not the highest, but offers near-complete protection against hospitalization and death. Also being tested as a two-dose regimen.

Trial Start Date - 07 September 2020
Result Publication Date - 29 January 2021
24 Nov, 2021: Complete Approval given by Canada
21 Oct, 2021: Emergency Use Authorization given by the US
16 Sep, 2021: Emergency Use Authorization given by Iran
07 Sep, 2021: Emergency Use Authorization given by Indonesia
07 Aug, 2021: Emergency Use Authorization given by India
28 Jul, 2021: Emergency Use Authorization given by Zimbabwe
15 Jul, 2021: Emergency Use Authorization given by Vietnam
7 Jul, 2021: Provisional approval given by New Zealand
5 Jul, 2021: Emergency Use Authorization given by Ukraine
25 Jun, 2021: Provisional approval given by Australia
15 Jun, 2021: Emergency Use Authorization given by Malaysia
15 Jun, 2021: Emergency Use Authorization given by Bangladesh
11 Jun, 2021: Emergency Use Authorization given by Chile
8 Jun, 2021: Emergency Use Authorization given by Kuwait
8 Jun, 2021: Emergency Use Authorization given by Maldives
2 Jun, 2021: Emergency Use Authorization given by Zambia
28 May, 2021: Conditional Marketing Authorization given by UK
28 May, 2021: Emergency Use Authorization given by Mexico
20 Apr, 2021: Emergency Use Authorization given by Philippines
8 Apr, 2021: Emergency Use Authorization given by Tunisia
07 Apr, 2021: Conditional Marketing Authorization given by South Korea
1 Apr, 2021: Emergency Use Authorization given by Brazil
21 Mar, 2021: Emergency Use Authorization given by Libya
26 Mar, 2021: Emergency Use Authorization given by Colombia
25 Mar, 2021: Emergency Use Authorization given by Thiland
26 Mar, 2021: Emergency Use Authorization given by Switzerland
12 Mar, 2021: Conditional Marketing Authorization given by Italy
12 Mar, 2021: Conditional Marketing Authorization given by France
12 Mar, 2021: Emergency Use Listing (EUL) given by WHO
11 Mar, 2021: Conditional Marketing Authorization given by EU
5 Mar, 2021: Emergency Use Authorization given by Canada
27 Feb, 2021: Emergency Use Authorization given by the US
25 Feb, 2021: Emergency Use Authorization given by the US
https://www.aljazeera.com/news/2021/2/17/south-africa-begins-vaccine-rollout-through-observational-study
Today

Gamaleya 33,758 2 2 - 8°C 91.4% 38

Developed by Russia, uses two different adenoviruses, one for each of two doses, as part of a heterologous vaccination plan. Has shown excellent efficacy of just over 90% in preventing all Covid-19.

Early Approval - 12 August 2020
Trial Start Date - 07 September 2020
Result Publication Date - 14 December 2020
7 Mar, 2021: Emergency Use Authorization given by Macedonia
4 Mar, 2021: Emergency Use Authorization given by Sri Lanka
3 Mar, 2021: Emergency Use Authorization given by Angola
3 Mar, 2021: Emergency Use Authorization given by Djibouti
3 Mar, 2021: Emergency Use Authorization given by Republic of the Congo
1 Mar, 2021: Emergency Use Authorization given by Slovakia
25 Feb, 2021: Emergency Use Authorization given by Guatemala
24 Feb, 2021: Emergency Use Authorization given by Egypt
24 Feb, 2021: Emergency Use Authorization given by Honduras
20 Feb, 2021: Emergency Use Authorization given by Ghana
19 Feb, 2021: Emergency Use Authorization given by San Marino
17 Feb, 2021: Emergency Use Authorization given by Gabon
17 Feb, 2021: Emergency Use Authorization given by Uzbekistan
12 Feb, 2021: Emergency Use Authorization given by Montenegro
10 Feb, 2021: Emergency Use Authorization given by Bahrain
9 Feb, 2021: Emergency Use Authorization given by Mongolia
9 Feb, 2021: Emergency Use Authorization given by Pakistan
6 Feb, 2021: Emergency Use Authorization given by Myanmar
6 Feb, 2021: Emergency Use Authorization given by Bosnia and Herzegovina
5 Feb, 2021: Emergency Use Authorization given by Lebanon
3 Feb, 2021: Emergency Use Authorization given by Mexico
3 Feb, 2021: Emergency Use Authorization given by Nicaragua
1 Feb, 2021: Emergency Use Authorization given by Armenia
30 Jan, 2021: Emergency Use Authorization given by Tunisia
29 Jan, 2021: Emergency Use Authorization given by Republic of Guinea
26 Jan, 2021: Emergency Use Authorization given by Iran
21 Jan, 2021: Emergency Use Authorization given by Hungary
21 Jan, 2021: Emergency Use Authorization given by UAE
18 Jan, 2021: Emergency Use Authorization given by Turkmenistan
15 Jan, 2021: Emergency Use Authorization given by Paraguay
13 Jan, 2021: Emergency Use Authorization given by Venezuela
11 Jan, 2021: Emergency Use Authorization given by Palestine
10 Jan, 2021: Emergency Use Authorization given by Algeria
6 Jan, 2021: Emergency Use Authorization given by Bolivia
28 Dec, 2020: Approved by Russia for population aged 60 years and above
23 Dec, 2020: Emergency Use Authorization given by Argentina
21 Dec, 2020: Emergency Use Authorization given by Belarus
12 Aug, 2020: Complete Approval given by Russia
Today

Sinovac Biotech 29,608 2 2 - 8°C 50.65% 12

Vaccine from China, one of few vaccines using inactivated SARS-CoV-2 viruses which is a much more conventional vaccine technology than others which have demonstrated positive Phase III data.

Early Approval - 11 January 2021
Trial Start Date - 21 July 2020
Result Publication Date - 05 February 2021
2 Mar, 2021: Emergency Use Authorization given by Malaysia
22 Feb, 2021: Emergency Use Authorization given by Philippines
22 Feb, 2021: Emergency Use Authorization given by Thailand
13 Feb, 2021: Emergency Use Authorization given by Cambodia
11 Feb, 2021: Emergency Use Authorization given by Mexico
8 Feb, 2021: Emergency Use Authorization given by China
5 Feb, 2021: Emergency Use Authorization given by Colombia
21 Jan, 2021: Emergency Use Authorization given by Chile
18 Jan, 2021: Emergency Use Authorization given by Brazil
13 Jan, 2021: Emergency Use Authorization given by Turkey
13 Jan, 2021: Emergency Use Authorization given by Turkey
11 Jan, 2021: Emergency Use Authorization given by Indonesia
Today

Sinopharm 60,000+ 2 2 - 8°C 86.0% 14

The second inactivated vaccine, also being developed by China, has shown mixed results in Brazil, where initial efficacy was 86% based on data from the UAE, but efficacy data from Brazil were significantly lower at only 50%.

Early Approval - 12 October 2020
Trial Start Date - 16 July 2020
Result Publication Date - 10 December 2020
26 Feb, 2021: Emergency Use Authorization given by Guyana
22 Feb, 2021: Emergency Use Authorization given by Argentina
4 Feb, 2021: Emergency Use Authorization given by Cambodia
29 Jan, 2021: Emergency Use Authorization given by Hungary
27 Jan, 2021: Emergency Use Authorization given by Peru
24 Jan, 2021: Emergency Use Authorization given by Morocco
19 Jan, 2021: Emergency Use Authorization given by Pakistan
19 Jan, 2021: Emergency Use Authorization given by Iraq
18 Jan, 2021: Emergency Use Authorization given by Republic of Serbia
9 Jan, 2021: Emergency Use Authorization given by Jordan
4 Jan, 2021: Emergency Use Authorization given by Egypt
2 Jan, 2021: Emergency Use Authorization given by China
14 Dec, 2020: Emergency Use Authorization given by Bahrain
10 Dec, 2020: Complete Approval given by UAE
Today

CanSino Biologics 40,000 1 2 - 8°C 65.7% 3

Like Johnson & Johnson’s vaccine, this vaccine from China showed just under 70% efficacy in preventing all Covid-19 and 90% efficacy in preventing severe Covid-19 with just a single dose.

12 Feb, 2021: Emergency Use Authorization given by Pakistan
11 Feb, 2021: Emergency Use Authorization given by Mexico
25 Jun, 2020: Military Use Authorization given by China
Trial Start Date - 15 September 2020
Today

Covid-19 vaccine clinical trials by region

Covid-19 vaccine clinical trials by trial phase

Covid-19 vaccine clinical trials by trial status

Covid-19 - The race to herd immunity

According to the World Health Organization (WHO), "Herd Immunity, also known as population immunity, is the indirect protection from an infectious disease that happens when a population is immune either through vaccination or immunity developed through previous infection."

Herd immunity against Covid-19 has been widely debated over the past months, however WHO has admitted, "we do not have a clear understanding of the herd immunity level for Covid-19."

So, what is the herd immunity percentage for Covid-19?

In the context of Covid-19, herd immunity level is 60-70%,but could be higher if the new variants of the virus are more contagious.

The assumption should always be higher rather than lower with some recent research suggesting the number of the population that needed to be vaccinated ranged from 69-93%.

Race to herd immunity (Top 20 countries by vaccination rate)

Race to herd immunity (Leading economies)

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU